BioSpace News Archive

Sanofi and Innate Pharma expand their longtime collaboration by licensing up to three NK cells engager programs in cancer immunotherapy valued at more than $1.4 billion.

Psychedelic and psychedelic-assisted therapies in the neuropsychiatric space have stalled for decades.

Pfizer is rapidly scaling up its AI/ML efforts in a collaborative effort intended to get transformative medicines to patients faster.

Madrigal’s NASH drug hits the mark in late-stage trial.

Myriad Genetics, Inc., a leader in genetic testing and precision medicine, announced the addition of five senior executives to help further strengthen the company’s product roadmap and improve commercial execution.

NewAmsterdam Pharma Company N.V., a clinical-stage company focused on the research and development of transformative oral therapies for major cardiometabolic diseases, announced the appointment of David Topper as Chief Financial Officer, effective January 1, 2023.

ARCA biopharma, Inc. announced that James Flynn has joined its Board of Directors.

Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced the appointments of Peter Atadja, Ph.D., and Trafford Clarke, Ph.D., as independent members of the Company’s Board of Directors.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its presentation at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023.

Illumina, Inc. announced that its executives will be speaking at the following investor conference.